OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

RECORDATI ORD/  IT0003828271  /

Euronext Milan (TAH)
2024-10-04  7:27:57 PM Chg. +2.35 Volume Bid8:30:00 PM Ask8:30:00 PM Market Capitalization Dividend Y. P/E Ratio
51.65EUR +4.77% 261
Turnover: 13,482.50		 -Bid Size: - -Ask Size: - 10.68 bill.EUR 2.31% 27.39
GlobeNewswire 2021-03-23 RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S AN...
GlobeNewswire 2021-02-22 RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBI...
GlobeNewswire 2021-01-29 RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
GlobeNewswire 2020-11-30 RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEA...
GlobeNewswire 2020-10-29 RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NE...
GlobeNewswire 2020-10-01 RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P....
GlobeNewswire 2020-09-21 RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
GlobeNewswire 2020-07-30 RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET IN...
GlobeNewswire 2020-06-17 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S D...
GlobeNewswire 2020-05-07 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
GlobeNewswire 2020-04-29 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
GlobeNewswire 2020-04-08 Recordati Rare Diseases now holds Isturisa® European MA
GlobeNewswire 2020-03-26 RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
GlobeNewswire 2020-03-18 RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY D...
GlobeNewswire 2020-03-18 BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). ...
GlobeNewswire 2020-02-14 RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBIT...
GlobeNewswire 2020-01-15 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
GlobeNewswire 2019-11-15 RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT)
GlobeNewswire 2019-10-31 RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING IN...
GlobeNewswire 2019-10-23 RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED
GlobeNewswire 2019-07-30 RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
GlobeNewswire 2019-07-12 RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)
GlobeNewswire 2019-06-24 RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
GlobeNewswire 2019-05-08 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED
GlobeNewswire 2019-04-15 RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY